# ACE Reno, Pico Cell Matrix and Its Effect on eGFR in Chronic Kidney Diseases

Study · id `cardio:ct-nct07187713` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07187713](<https://clinicaltrials.gov/study/NCT07187713>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07187713

Browse, organ or system: Kidneys; Metabolism  
Browse, condition area: Diabetes and metabolic disease; Kidney connections  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 300 participants.

## Technical summary

Registry record NCT07187713. Allocation not applicable; no masking; primary purpose treatment. Start 2025-09-20 (anticipated); primary completion 2026-08-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 300 participants (planned count; ClinicalTrials.gov record NCT07187713, source copy `cardio:ctgov-nct07187713-2025-09-23`, retrieved 2026-10-26)
- Planned start: 2025-09-20 (anticipated) (ClinicalTrials.gov record NCT07187713, source copy `cardio:ctgov-nct07187713-2025-09-23`, retrieved 2026-10-26)
- Primary completion: 2026-08-31 (anticipated) (ClinicalTrials.gov record NCT07187713, source copy `cardio:ctgov-nct07187713-2025-09-23`, retrieved 2026-10-26)
- Completion: 2026-12-31 (anticipated) (ClinicalTrials.gov record NCT07187713, source copy `cardio:ctgov-nct07187713-2025-09-23`, retrieved 2026-10-26)
- Countries: Egypt (ClinicalTrials.gov record NCT07187713, source copy `cardio:ctgov-nct07187713-2025-09-23`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07187713-2025-09-23`, retrieved 2026-10-26)

## The registry's words

- Brief title: ACE Reno, Pico Cell Matrix and Its Effect on eGFR in Chronic Kidney Diseases
- Acronym: ACE Reno
- Condition: Hypertensive Nephropathy
- Condition: Auto Immune Disorders
- Condition: Chronic Kidney Disease
- Condition: Chronc Kidney Disease Stage 5
- Condition: Chronic Kidney Disease (Stage 3-4)
- Condition: Chronic Kidney Disease (Stages 4 and 5)
- Condition: Microalbuminuria
- Condition: Diabetic Nephropathies
- Intervention (Drug): ACE Reno
- Lead sponsor: Ace Cells Lab Limited
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry condition terms include this condition: Diabetic kidney disease (`cardio:diabetic-nephropathy`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)

## Provenance

Content hash: a94b850b67239c0194df4544e264a4a9bdaecc49eb542ce13d7eca5006efd356
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
